Short-term clinical study of butylphthalide sodium chloride injection combined with rt-PA intravenous thrombolysis for 47 patients with acute ischemic stroke

Abstract

Objective To investigate the short-term clinical effect of butylphthalide sodium chloride injection combined with intravenous thrombolysis and ateprase (rt-PA) in the treatment of acute ischemic stroke (AIS). Methods 94 patients with AIS treated at our hospital from March, 2016 to July, 2018 were selected and randomly divided into a control group and an observation group, 47 cases for each group. Both groups were given routine treatment, such as fluid infusion, oxygen inhalation, and anti-platelet aggregation. The control group were given rt-PA intravenous thrombolysis. The observation group were given butylphthalide sodium chloride injection and rt-PA intravenous thrombolysis. Both groups were treated for 14 days. The Clinical efficacies, incidences of adverse reactions, cerebral infarction volumes before and after treatment, and serum levels of hypersensitive-C-reactive protein (hs-CRP), S100β protein (S100β), and neuron-specific enolase (NSE) as well as neurological deficit (NIHSS) score were compared between the two groups. Results The total effective rate was higher in the observation group than in the control group [93.62% (44/47) vs. 78.72% (37/47), P 0.05). Conclusions Butylphthalide sodium chloride injection combined with rt-PA intravenous thrombolysis in the treatment of AIS patients is effective, can reduce the cerebral infarction volume and the serum levels of hs-CRP, S100beta, and NSE, alleviate inflammation, and promote the recovery of neurological function, and does not significantly increase adverse reactions, so it can provide guidance for clinical treatment of AIS. Key words: Acute ischemic stroke; Butylphthalide sodium chloride injection; Alteplase; Thrombolysis; Neurological function